Nilotinib Stada Arzneimittel

Nilotinib, the active ingredient in Nilotinib Stada Arzneimittel, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of Philadelphia chromosome‑positive chronic myeloid leukemia in adult patients with documented efficacy and a manageable safety profile.

GNH USA supplies Nilotinib Stada Arzneimittel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable access to high‑quality oncology medicines and supporting therapeutic programs across diverse healthcare systems.

Nilotinib targets the BCR‑ABL tyrosine‑kinase pathway and is indicated for Philadelphia chromosome‑positive chronic myeloid leukemia. - Chronic phase CML (first‑line): Reduces disease burden and prolongs survival in newly diagnosed patients. - Accelerated phase CML (after prior therapy): Achieves hematologic and cytogenetic responses in patients who have progressed. - Chronic or accelerated phase CML after imatinib resistance or intolerance: Provides an alternative targeted option when first‑line tyrosine‑kinase inhibitors are ineffective.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Fatigue: reduced energy levels. - Rash: skin erythema or pruritus. - Elevated liver enzymes: mild transaminase increase. - Myalgia: muscle aches. - Headache: occasional mild headache. - Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusive disease or ischemia. - Pancreatitis: inflammation of the pancreas. - Severe hepatotoxicity: marked liver injury. - QT interval prolongation: risk of cardiac arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Nilotinib, clinicians should observe several precautionary measures to minimize risks. - Cardiac assessment: evaluate baseline cardiovascular status and monitor for ischemic events. - Electrolyte monitoring: check serum potassium and magnesium to reduce QT prolongation risk. - Liver function: perform baseline and periodic liver enzyme tests. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors or inducers. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with patient. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Nilotinib interacts with several medicines; awareness of major and moderate interactions guides safe co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase Nilotinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can substantially reduce drug levels. - Antacids containing aluminum or magnesium: decrease absorption if taken concurrently.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may lower bioavailability; separate dosing times. - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): increased risk of statin toxicity. - Anticoagulants (warfarin): monitor INR as Nilotinib may affect coagulation parameters.